Literature DB >> 8040845

Obstetric and gynecologic dysfunction in the Ehlers-Danlos syndrome.

Y Sorokin1, M P Johnson, N Rogowski, D A Richardson, M I Evans.   

Abstract

Women members of the newly formed Ehlers-Danlos National Foundation (EDNF) were surveyed with a very detailed questionnaire with 50 questions concerning family history and inheritance, past medical history, and obstetric and gynecologic problems. They entailed the largest extant database on Ehlers-Danlos Syndrome (EDS) patients. The mean age of the 68 women who responded to the survey was 42 years; most had EDS types I, III, IV and unknown. Forty-three women had 138 pregnancies; 13 women never married. The stillbirth rate was 3.15% (3/95); the preterm delivery rate was 23.1% (22/95), and the spontaneous abortion rate was 28.9% (40/138). There was a cesarean delivery rate of 8.4%, with 14.7% having perinatal bleeding problems. One woman (EDS type IV) had congestive heart failure. Common gynecologic problems were recurrent anovulation (41.3%), recurrent vaginal infections (53%), abnormal cytologic smears (19%), sexual dysfunction (61%), irregular menses (28%), endometriosis (15.8%), vaginal dryness (25%) and a need for hysterectomy (19.1%). In this largest series of pregnancies with EDS, we found relatively high rates of abortion, preterm delivery, pregnancy-related bleeding and stillbirth. Women with EDS also seem to have high frequency of anovulation, vaginal infections, abnormal cytologic smears and dyspareunia.

Entities:  

Mesh:

Year:  1994        PMID: 8040845

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  12 in total

Review 1.  Urogenital and pelvic complications in the Ehlers-Danlos syndromes and associated hypermobility spectrum disorders: A scoping review.

Authors:  Elizabeth Gilliam; Jodi D Hoffman; Gloria Yeh
Journal:  Clin Genet       Date:  2019-09-01       Impact factor: 4.438

2.  Spontaneous rupture of liver in a patient with Ehlers Danlos disease type IV.

Authors:  C M Gelbmann; M Köllinger; J Gmeinwieser; H G Leser; A Holstege; J Schölmerich
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

3.  Use of porcine small intestinal submucosa in the surgical treatment of recurrent rectocele in a patient with Ehlers-Danlos syndrome type III.

Authors:  Chrysanthi Sardeli; Susanne M Axelsen; Karl M Bek
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-01-12

4.  Ehlers-Danlos syndrome and other heritable connective tissue disorders that impact pregnancies can be detected using next-generation DNA sequencing.

Authors:  Krystal VanderJagt; Merlin G Butler
Journal:  Arch Gynecol Obstet       Date:  2019-06-27       Impact factor: 2.344

5.  Association of Maternal Versus Fetal Ehlers-Danlos Syndrome Status with Poor Pregnancy Outcomes.

Authors:  L A Underhill; C Barbarita; S Collis; R Tucker; B E Lechner
Journal:  Reprod Sci       Date:  2022-06-08       Impact factor: 3.060

6.  Successful vaginal birth after caesarean section in patient with Ehler-Danlos syndrome type 2.

Authors:  Hemant Maraj; Michelle Mohajer; Deepannita Bhattacharjee
Journal:  Obstet Med       Date:  2011-10-27

Review 7.  A case report of obstetrical management of a pregnancy with hypermobile Ehlers-Danlos syndrome and literature review.

Authors:  H Khalil; J Rafi; T T Hla
Journal:  Obstet Med       Date:  2013-05-03

Review 8.  Connective tissue and related disorders and preterm birth: clues to genes contributing to prematurity.

Authors:  E A Anum; L D Hill; A Pandya; J F Strauss
Journal:  Placenta       Date:  2009-01-18       Impact factor: 3.481

9.  Pregnancy and delivery in ehlers-danlos syndrome (hypermobility type): review of the literature.

Authors:  Indranil Dutta; Helen Wilson; Odiri Oteri
Journal:  Obstet Gynecol Int       Date:  2011-06-15

10.  Ehlers-danlos syndrome, hypermobility type: an underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations.

Authors:  Marco Castori
Journal:  ISRN Dermatol       Date:  2012-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.